Antibody drugs such as monoclonal antibodies (mAb), bispecific antibodies, antibody-drug conjugates (ADCs), and nanobodies garnered increased interest in research and development circles. Sino ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. In April 2021, the FDA approved the 100th monoclonal ...

Given the multifaceted nature of ADCs, developers should have an integrated analytical toolkit. Three complementary approaches dominate the current landscape: Ligand Binding Assays (LBA): Ideal for ...

For therapies based on monoclonal antibodies (mAbs), bioprocessors continually search for ways to improve the development process. Machine learning (ML) offers one useful tool. As Mariano Nicolas Cruz ...

Researchers used Google DeepMind’s AlphaFold2 and ProteinMPNN to speed development of antibody-based probes that can be used to see key functions and chemical changes inside living cells as they ...

This article is based on a poster originally authored by An Ouyang, Spencer Chiang and Chao Wang. Antibody-drug conjugates (ADCs) are a new class of anti-cancer therapeutics that are both novel and ...

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a significant ...

"JPM26: SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody" was originally created and published by ...